The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2017.04.009
Abstract: PURPOSE Delafloxacin is a novel anionic fluoroquinolone in Phase III development for the treatment of serious skin infections. The objective of this study was to evaluate the effects of delafloxacin on the pharmacokinetics of midazolam,… read more here.
Keywords: midazolam; state dosing; steady state; dosing delafloxacin ... See more keywords